Micronutrient and macronutrient dietary intervention and the progression of Alzheimer's disease by Yan, Pamela
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2017
Micronutrient and macronutrient
dietary intervention and the
progression of Alzheimer's disease
https://hdl.handle.net/2144/26898
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
MICRONUTRIENT AND MACRONUTRIENT DIETARY INTERVENTION 
AND THE PROGRESSION OF ALZHEIMER’S DISEASE 
 
 
by 
 
 
 
 
PAMELA YAN 
 
B.A., University of Southern California, 2016 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2017  
	 	 	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 by 
 PAMELA YAN 
 All rights reserved 
	 	 	
	
Approved by 
 
 
 
 
First Reader __________________________________________________________ 
 Ivana Delalle, M.D., Ph.D. 
 Associate Professor of Neurology 
  
 
 
Second Reader __________________________________________________________ 
 Simon Levy, Ph.D. 
 Associate Professor of Physiology and Biophysics  
	 	 	
	iv	
ACKNOWLEDGEMENTS 
 
Thank you to Dr. Delalle and Dr. Levy who, without their insight and contribution, I 
would not have been able to write this work. Thank you also to the Boston University 
School of Medicine for providing me access to literature and the opportunity to write this. 
Thank you to my coworkers at the University of Southern California Memory and Aging 
Center for fostering my interest in this area of research.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 	 	
	v	
MICRONUTRIENT AND MACRONUTRIENT DIETARY INTERVENTION 
AND THE PROGRESSION OF ALZHEIMER’S DISEASE 
 
PAMELA YAN 
 
ABSTRACT 
Alzheimer’s Disease (AD) is the most common neurodegenerative brain disease 
worldwide. It primarily affects older adults and is characteristically marked by memory 
loss correlated with loss of functional brain tissue. As the human lifespan increases and 
without effective treatment, the number of people at-risk for AD will rise dramatically in 
the near future. Identifiable genotypic risk factors or causes are only present in a small 
number of AD patients, and thus environmental factors potentially exacerbating the 
disease should be examined. Here I reviewed the results of clinical trials examining the 
role of nutritional components in AD with the following conclusions. First, there are still 
not enough trials on nutrients affecting onset and progression of AD. Reasons include 
ethical difficulties of randomized studies controlling for nutrients that are important for 
overall human health. Thus, conclusions about cognitive benefits of such nutrients remain 
unknown.  Second, the dosages, treatment lengths, and disease time points investigated 
are varied between studies, with varying results as well. However, studies that examined 
the role of dietary intervention in early-stage patients report more significant benefits. 
Third, the interaction of multiple facets of nutrition and general lifestyle factors may act 
in synergy to affect disease onset and progression. Finally, and perhaps most importantly, 
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this review reiterates that neuronal loss, i.e. advanced AD, currently cannot be cured. 
Instead, the prevention and slow-down of the disease should be approached from as many 
angles as possible, including nutrition, exercise and social activities, as these factors 
influence human life every day over many years, affecting the health of the entire body, 
including the brain.  
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INTRODUCTION 
 
THE EMERGENT NEED FOR ALZHEIMER’S INTERVENTION 
In recent estimates, 35.6 million people worldwide lived with dementia in 2010, a 
number that is projected to reach 115.4 million people by 2050 (Prince et al., 2013). 
Alzheimer’s Disease (AD) is the most common type of dementia and the most common 
neurodegenerative disease worldwide and the increasing age of the global population 
presents an emergent health crisis {(Mangialasche et al., 2010) (Corbett & Ballard, 2012) 
(Imtiaz, Tolppanen, Kivipelto, & Soininen, 2014) (Sezgin & Dincer, 2014)}. 
 
It is imperative for healthcare professionals to mobilize resources immediately to combat 
this growing epidemic. In general, health outcomes may benefit substantially from both 
preventive methods to lower incidence as well as treatment methods for those already 
living with the disease in order to slow progression (Prince et al., 2013).  
  
TREATMENT IN THE NEAR FUTURE 
There is no current treatment that can prevent, stop, or reverse the progression of AD 
{(Huang & Mucke, 2012) (Sezgin & Dincer, 2014) (Sindi, Mangialasche, & Kivipelto, 
2015)}. Existing treatments may slow the progression of clinical symptoms in some 
patients, but the average efficacy period is only 6 months (Corbett & Ballard, 2012). 
Many clinical and experimental studies are ongoing, but a single cure for AD is unlikely 
to be found in the near future considering the disheartening lack of new treatments for the 
disease in the research pipeline (Mangialasche, Solomon, Winblad, Mecocci, & 
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Kivipelto, 2010). Though there may be clinical studies ongoing for AD immunotherapy, 
the number of compounds making it to regulatory review for AD is among the lowest 
found in any area of therapy (Cummings, Morstorf, & Zhong, 2014). Upon review of all 
available papers on PubMed written about Phase III immunotherapy AD trials since 
2012, it appears that every Phase III drug treatment in the last five years has not passed 
review. These disappointing results make the words of Solomon et al. (2014) even more 
poignant: “The field of AD research has advanced to where it is no longer necessary to 
justify the importance of prevention as the main therapeutic goal”. The long latency 
period between exposure and clinical symptoms for AD means that any randomized 
controlled prevention trials will take a long time to reach any conclusive results about 
causation. All the while, there are 3.3 million new cases of AD appearing worldwide each 
year (Barnard et al., 2014).  
 
The urgency of addressing the AD epidemic justifies reviewing the large body of 
literature on non-pharmacologic risk and protective factors that influence outcomes in the 
pre-clinical stage of AD (Sindi, Mangialasche, & Kivipelto, 2015) (Figure 1). Given the 
long course of influence that lifestyle factors have upon an individual’s AD health 
outcomes, we may benefit from establishing which lifestyle factors consistently influence 
human cognition positively and may prevent or delay cognitive decline in AD (Solomon 
et al., 2014) (Figure 1). 
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Figure 1. Risk factors for dementia and AD across the human lifespan. (Sindi, 
Mangialasche, & Kivipelto, 2015). 
 
 
Nutritional choices represent a lifestyle factor impacting individuals over their lifetime. 
Clinicians have the ability to influence nutritional choices of their patients by formulating 
recommendations backed by evidence from critically reviewed public health studies, 
clinical and basic science research.  
There are ethical limitations in restricting nutrition in randomized controlled trials 
over the long latent period pre-disease. According to Blumberg et al. (2012), nutrition 
recommendations may be implemented at a different level of confidence than a 
pharmaceutical substance in preventing disease (Table 1). In other words, significant 
associative evidence combined with the evidence against significant risk of harm may be 
sufficient for clinicians to compare a dietary program to a novel pharmaceutical drug 
(Barnard et al. 2014). Clinicians at the International Conference on Nutrition and the 
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Brain in 2013 concluded that some non-pharmacological food substances, presented in 
the handful of AD clinical trials with no significant risk, warrant recommendation in 
clinical practice (Barnard et al., 2014). 
 
Table 1. Summary panel of main issues and recommendations concerning 
AD/dementia prevention. (Solomon et al., 2014). 
 
 
AD PATHOLOGY 
The AD progressive brain pathology consists of hallmark extracellular amyloid neuritic 
plaques and intracellular neurofibrillary tangles formed by abnormally phosphorylated 
tau protein that may develop many years before clinical expression (Reitz & Mayeux, 
2014) (Kumar, Abbas, & Aster, 2012). These morphological changes correlate strongly 
to synaptic dysfunction, neuronal death, and loss of cognitive function {(Selkoe, 2005) 
(Kumar, Abbas, & Aster, 2012) (Pozueta et. al, 2013) (Reitz & Mayeux, 2014) (Dean et 
al., 2017)}. 
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AD cascade hypothesis postulates that the soluble Abeta (amyloid beta peptide) oligomer 
accumulation in the brain initiates a series of events that negatively affect morphology 
and functions of brain structures leading to pathological decline in cognitive performance 
{(Selkoe, 2005) (Terry, 2006) (Kumar, Abbas, & Aster, 2012) (Sheng, Sabatini, & 
Südhof, 2012) (Pozueta et al., 2013) (Spires-Jones & Hyman, 2014)} (Figure 2). 
Individuals with mutations of the gene encoding the Abeta precursor protein (APP) or in 
the presinilin genes encoding the enzyme that cleaves APP into Abeta that lead to an 
increased rate of Abeta production will develop familial AD (Kumar, Abbas, & Aster, 
2012). Individuals with Down syndrome trisomy, and thus a third copy of the APP gene, 
also have a highly increased risk of developing AD . Although these genetic cases helps 
support Abeta as a pathological initiator, sporadic onset cases are the vast majority and 
the cause of this sporadic AD pathology is unknown (Kumar, Abbas, & Aster, 2012). 
 
Randomized controlled trials are being conducted on nutritional interventions attempting 
to modulate the proposed cascade pathogenesis. Some investigate preservation of 
synaptic function in AD by supplementing dietary synaptic precursors, or by controlling 
insulin, a ubiquitous dietary signaling molecule that has shown interaction with Abeta 
{(Felice et al., 2009) (Larson & Lesné, 2012) (van Wijk et al., 2014)}. 
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Figure 2. Model of Abeta42 concentrations in the CSF and brain parenchyma 
throughout AD patient’s lifespan. Note the tipping point before clinical detection where 
Abeta continues to accumulate within the parenchyma, forming plaques, but decreases in 
the CSF. aMCI= amnestic mild cognitive impairment. Aβ42= amyloid beta peptide, 42 
amino acid variant. (Bayer-Carter et al., 2011).  
 
 	
OXIDATIVE STRESS IN AD 
Oxidative stress in the brains of AD patients has been compared to normal older adults 
suggesting that it may play a role in the AD neuronal degeneration (Markesbery & 
Carney, 1999). The oxidated residues in AD brains have a significant negative correlation 
with cognitive performance on the Mini-Mental State Examination (Ahmed et al., 2005). 
Consequently, associative studies have been investigating how lifestyle factors may 
correlate with the oxidative damage. The findings of multiple associations between 
compounds naturally found in the human diet and oxidation status of proteins, 
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lipoproteins, and phospholipids necessary for brain function has prompted randomized 
controlled trials in human subjects. 
 
BRAIN RESERVE 
Brain reserve is the ability to resist clinical cognitive decline even with hallmark brain 
morphology of AD (Katzman et al., 1988). Individuals with mild AD brain pathology and 
greater brain reserve, correlated with larger brain weight and greater number of neurons, 
had better cognitive function than age-matched controls without AD pathology and 
average reserve (Katzman et al., 1988). Factors experienced across the entire lifespan 
including education, social network, and leisure activities may contribute to brain reserve 
and prevent cognitive decline later in life {(Fratiglioni & Wang, 2007) (Perani et al., 
2017)}. In rats, supplementation with docosahexanoic acid in diet has been shown to 
confer neuroprotection (Wu, Ying, & Gomez-Pinilla, 2008). Randomized clinical trials 
have investigated this angle on AD prevention by modulating said lifestyle factors.  
 
 
 
 
 
 
 
	8 
SPECIFIC AIMS 
1. Highlight difficulties of studying the effect of nutrition on AD. 
2. Outline various clinical trials that have been conducted in spite of this difficulty. 
3. Discuss mechanisms of these nutrient interventions in the AD pathogenesis.  
4. Discuss key takeaways from results of previous clinical trials. 
5. Discuss multivariate influence of lifestyle factors on AD. 
6. Discuss precautionary risks and areas for further research. 
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MICRONUTRIENTS AND AD 
Micronutrients are substances that are not produced in the body that are necessarily 
obtained from the diet, in small concentrations, for the body to produce enzymes, 
hormones, and other molecules that are essential for life (Centers for Disease Control and 
Prevention, 2015). Certain necessary dietary micronutrients have shown abnormal levels 
in the cerebrospinal fluid and plasma of AD patients, leading to studies modulating their 
intake.  
 
Vitamin E 
The rate of autoxidation of proteins and lipids in plasma of AD patients was 
significantly lower (p<0.001) in patients with higher concentrations of plasma 
Vitamin E alpha-tocopherol (Schippling et al., 2000). 
 
Vitamin C 
AD patients have less vitamin C in both their plasma and their CSF compared to 
normal controls (Schippling et al., 2000). Vitamin C concentrations in the 
cerebrospinal fluid (CSF) and plasma are negatively correlated with the rate of 
autoxidation of proteins and lipids in the respective bodily fluids (Schippling et 
al., 2000). 
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Carotenoids 
Patients with AD exhibit lower concentrations of macular pigment, an 
accumulation of carotenes in the macula of the eye, than normal controls (Nolan 
et al., 2014). Plasma concentrations of the carotenoids alpha carotene, lutein and 
zeaxanthine, were significantly lower in AD patients. 
 
B vitamins 
Homocysteine has been noted as a marker of hippocampal neuron loss in 
transgenic mice with AD amyloid pathology (Kruman et al., 2002). Vitamin B12 
plus folic acid has been shown to decrease serum homocysteine levels in humans 
(Malouf, Grimley, & Areosa, 2003).  
 
Phosphatidylserine 
Phosphatidylserine is an integral component of both the neuronal and plasma cell 
membranes (Mozzi, Buratta, & Goracci, 2003). A lower composition of 
phosphatidylserine is found in the membranes of red blood cells in AD patients 
compared to age-matched controls (Oma et al., 2012). 
 
Polyunsaturated fatty acids 
CSF concentrations of polyunsaturated fatty acids, a major component of 
lipoproteins in the brain, was found to be significantly lower in AD patients than 
that of healthy controls (Schippling et al., 2000). As a common substrate for 
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oxidation reactions, polyunsaturated fatty acid could be lowered as a result of 
reserves being depleted in a chemical environment promoting oxidation 
(Schippling et al., 2000). 
 
F2-Isoprostane 
This compound, a marker of oxidative stress, is elevated significantly in the brains 
of AD patients (Montine et al., 2011) and those with mild cognitive impairment in 
a possible prodromal stage of AD (Praticò et al., 2002).  
 
Carbonyl proteins 
Carbonyl proteins are markers of oxidative stress in neurodegeneration and are 
significantly increased in AD patients as opposed to normal controls (Rommer et 
al., 2014).  
 
Given these observations, the scientific community attempted to study the effect of intake 
of these micronutrients. Some micronutrients progressed to clinical trials. 
 
VITAMIN E 
Vitamin E is naturally found in the human diet from a variety of different sources and 
was studied in several randomized controlled human trials for its antioxidant capabilities. 
Its biologically active alpha-tocopherol form is found in nuts, seeds, and vegetable oils 
(Table 2) (“USDA National Nutrient Database for Standard Reference, Release 24.,” 
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2011). Soybean, corn and canola oils provide gamma-tocopherol, the largest, yet 
ineffective, source of vitamin E in the American diet (“USDA National Nutrient 
Database for Standard Reference, Release 24.,” 2011).  
 
Table 2. Notable food sources of vitamin E’s bioactive alpha-tocopherol form in a 
typical American diet. (“USDA National Nutrient Database for Standard Reference, 
Release 24.,” 2011). 
 
 
(Sano et al., 1997) 
In a hallmark study, cited by 1,111 other articles on PubMed, that began much of the 
scientific fervor for vitamin supplementation for AD, vitamin E supplementation 
significantly delayed functional deterioration in patients. Functional deterioration was 
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defined by the study as any of the following: death, maximum clinical dementia rating, 
loss of a majority of the activities of daily living, or a need for institutionalization.  
 
In the overall cohort, there was no significant improvement in cognitive performance. 
However, notably, there were significant results if adjusted for baseline scores on the 
Mini-Mental State Examination. There were no side effects reported, although there did 
seem to be a significantly greater number of falls in the vitamin E treatment group. 
The patients studied here were all moderately impaired at the beginning of the study. 
Given the insidious progression of the disease and accumulation throughout one’s 
lifetime of amyloid (Figure 2), perhaps more preclinical intervention trials could be 
undertaken. 
 
(Morris et al., 2002) 
In a large association study of 2889 older adults there was a statistically significant 
correlation between total vitamin E intake in diet and supplements and endpoint cognitive 
testing when compared to baseline 18 months prior. When researchers excluded 
participants with possible cognitive impairment at baseline (defined as score<25 on the 
Mini-Mental State Examination) the association between vitamin E intake and cognitive 
performance was even stronger. This points to a greater benefit of vitamin E intake while 
at a more preclinical cognitive state. Interestingly, this study showed limited association 
between cognitive decline and carotene or vitamin C intake, something that other studies 
have sought to examine with differing results as discussed below. This study also 
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suggests similar effects of Vitamin E from both dietary intake and supplement intake, 
something to note if conclusions are replicated enough to reach clinical recommendation 
and implementation. Generally, intake through a regular dietary incorporation of some 
Vitamin E-rich foods (Table 2) would be less disruptive and less likely to cause some of 
the problems with vitamin over-supplementation that are outlined.  
 
(Apostolova et al., 2013) 
A group of 110 participants with mild cognitive impairment, a possible prodromal stage 
of AD, were given either 1) donepezil, an experimental pharmacological agent for AD, 2) 
vitamin E or 3) placebo treatment for 3 years. The proportion of participants in the 
donepezil, vitamin E, and placebo groups whose mild cognitive impairment (MCI) 
developed into AD and whose mild cognitive impairment showed no such pathological 
change were nearly the same. Effectively, this study showed that there was indeed, no 
difference between supplementation groups and placebo (Table 3). There were no side 
effects reported. One note to make here is that all patients were already cognitively 
impaired. Perhaps the intervention began too late in the cumulative disease progression of 
AD to make a difference. 
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Table 3. Demographics of patients with MCIc and patients with MCInc after 3 years 
in one of three different interventions groups.  MCIc = mild cognitive impairment 
changing to AD. MCInc = mild cognitive impairment with no change to AD. (Apostolova 
et al., 2013).  
 
 
Comment: 
There is no evidence of adverse effects from the consumption of vitamin E naturally 
occurring in foods (Institute of Medicine, 2000). The safety of vitamin E alpha-
tocopherol supplementation has been shown up to 3200 mg/ day, or 4800 IU for several 
months (Institute of Medicine, 2000). For reference, the recommended dietary intake of 
the National Institute of Health for vitamin E is 22IU per day for adults.  
 
That being said, vitamin supplementation in high doses over a long period of time 
remains to be investigated for negative effect. Therapeutic supplementation in the long 
term to prevent the progressive course of AD should only ensue in clinical 
recommendation after further research.  
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More studies also need to be done with patients who are cognitively normal or presumed 
in a potential preclinical stage of AD. In the Morris study and the Sano study, the 
relationship between vitamin E intake and improvement or prevention of decline in 
cognition was stronger in people with higher baseline cognitive performance. This 
supports the model of AD as a long-course progressive disease where early intervention 
is the key. 
 
VITAMIN C 
Vitamin C, or ascorbic acid, is found in many fruits and vegetables common in the 
American diet (Table 4). 
 
 
Table 4. Notable food sources of vitamin C in a typical American diet. (“USDA 
National Nutrient Database for Standard Reference, Release 24.,” 2011). 
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(Kontush et al., 2001) 
A study of 20 patients with AD created two groups: one group received 400IU of vitamin 
E per day and the other group received 1000mg vitamin C and 400IU of vitamin E. Both 
conditions showed vitamin concentration increase in the plasma and CSF, indicating 
penetrability of the blood brain barrier through intake. 400IU of vitamin E alone was 
unable to decrease the oxidation of lipoproteins in the CSF. However, it appears that the 
dosage of vitamin C along with vitamin E had the greatest protective effect in the brain of 
mildly cognitively impaired and normal patients. The anti-oxidative effects of 
400IU/1000mg vitamin E and C supplementation in conjunction did decrease the 
abnormally elevated lipoprotein oxidation rate seen in the brain of AD patients (Figure 
3).  The dual supplementation also brought the abnormally decreased values of 
polyunsaturated fatty acids in the CSF and plasma of AD patients back up to the average 
for age-matched controls. There were no side effects and the treatment was well 
tolerated. This study is notable, like several others discussed, in that patients who were 
less impaired at the beginning of the study seemed to receive a beneficial effect. This 
study also seems to negatively support the conclusions made by some studies on vitamin 
E alone and its therapeutic benefit (at least as a stand-alone supplement). 
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Figure 3. Rate of CSF lipoprotein oxidation by AAPH in vitamin supplementation 
treatment groups. Different phases of oxidation reaction were recorded: A) the lag 
phase and B) the propagation phase. Note the oxidation rate in CSF of patients before and 
after receiving Vitamin E 400IU compared to receiving Vitamin C 1000mg and Vitamin 
E 400IU in combination. AAPH= 2,2'-azobis (2-amidinopropane) dihydrochloride (a 
water soluble generator of free radicals). (Kontush et al., 2001). 
 
 
(Galasko et al., 2012) 
In a 16-week study of 78 subjects with mild to moderate AD disease, one group was 
treated with 800IU of vitamin E, 500mg of vitamin C and 900mg of alpha lipoic acid 
(another antioxidant), a second group was treated with 1200mg of coenzyme Q (a 
enzyme required for metabolism), and a third group received placebo. According to this 
study, the two treatment groups both had no change in CSF biomarkers related to 
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amyloid or tau pathology. However, the group treated with vitamin E, C and alpha lipoic 
acid did show lowered F2-isoprostane levels (Table 5), although with a significantly 
accelerated decline in Mini-Mental State Examination as compared to placebo. There 
were no other side effects and medication was well tolerated. 
 
Table 5. Changes in CSF AD biomarkers with vitamin E/vitamin C/ alpha lipoic 
acid treatment, Coenzyme Q treatment, and placebo. 8 = p<0.05. E/C/ALA= vitamin 
E/vitamin C/alpha lipoic acid CoQ=coenzyme Q. (Galasko et al., 2012).  
 
 
 
Comment: 
No significant side effects were reported for these studies. There is no evidence 
suggesting that vitamin C is carcinogenic or teratogenic, and even at high doses from 
food and supplements, the adverse effect risk appears to be low (Institute of Medicine, 
2000). High vitamin C intakes have indicated low toxicity (Johnston, 1999). The upper 
limit of vitamin C intake for adults recommended by the Institute of Medicine (2000) is 
2000 mg/day, and adverse effects were observed after 3000mg/day. There is a very low 
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likelihood that someone eating a regular diet with vitamin C intake coming from dietary 
sources would approach that upper limit (Institute of Medicine, 2000). That being said, 
high dosage supplementation with vitamin C may have its own risks.  
 
It is difficult to compare the studies presented here as they used different mixtures of 
antioxidants.  Vitamin C alone as an antioxidant in prophylactic AD therapy needs 
randomized clinical trials to reach any conclusive evidence of such. There appears to be a 
link between dietary intake of Vitmain C and lowered markers of oxidative stress. 
However, the correlation between lowered oxidative stress and the cognitive status 
remains to be established. 
 
CAROTENOIDS 
Carotenoids are a broad class that refers to molecules such as lutein, zeaxanthin, and 
mesozeaxanthin. In nature, carotenoids are found in fruits and vegetables as part of a 
regular healthy diet. They scavenge free radicals that cause oxidative damage, such as 
oxygen and hydroxyl species, in the retina (Trevithick-Sutton, Foote, Collins, & 
Trevithick, 2006).  Carotenoids, particularly lutein and zeaxanthin, preferentially 
accumulate in the human brain and cross the retinal-blood barrier, forming macular 
pigment (Johnson, 2012).   
 
The severity of cognitive impairment in AD is significantly associated with the amount of 
carotenoids in plasma (Wang, Shinto, Connor, & Quinn, 2008). Perhaps the mechanisms 
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behind this effect are the antioxidant and anti-inflammatory abilities of carotenoids, 
already demonstrated in the retina. Given the high concentration of carotenoids in both 
the retina and the brain, they could be investigated for similar effectiveness in the brain as 
in the retina. In fact, macular pigment is significantly correlated with brain concentration 
of the carotenoids in primates (Vishwanathan, Neuringer, Snodderly, Schalch, & 
Johnson, 2013).  
 
Abeta peptides have been shown to damage red blood cells via lipid peroxidation, leading 
to decreased blood delivery to the brain and thus potentiating brain damage in AD 
(Nakagawa et al., 2011). Carotenoids have been shown to prevent this red blood cell 
damaging effect of Abeta (Nakagawa et al., 2011). 
 
(Kelly et al., 2015) 
In a study of elderly participants with normal cognition but with age-related macular 
degeneration, supplementation with carotenoids increased serum and optical density of 
the carotenoids. The increase in the serum was positively correlated with optical density 
of macular pigment. After Kelly et al. administered intervention or placebo, they found 
that macular pigment and serum concentrations of carotenoids increased in the treatment 
group. Additionally, participants’ macular pigment concentrations were positively 
correlated with better performance on several cognitive tests (Figure 4). After adjustment 
for confounding factors of diet, age, education level, and gender, the correlation between 
macular pigment and the higher cognitive scoring on multiple tests was still significant. 
	22 
 
 
 
Figure 4. Correlations between macular pigment concentrations (x) and cognitive 
test scores (y) in early age-related macular degeneration patients with normal 
cognition. a) word fluency score vs. macular pigment optical density=0.25 b) word 
fluency score vs. macular pigment optical density 0.5 c) animal fluency vs. macular 
pigment optical density=0.25 d) animal fluency vs. macular pigment optical density 0.5 
e) attention switching task percent correct vs. macular pigment optical density 0.25 f) 
attention switching task percent correct vs. macular pigment optical density 0.5 g) paired 
associated learning total errors adjusted vs. macular pigment optical density 0.25 h) 
paired associated learning total errors adjusted vs. macular pigment optical density 0.5  
(Kelly et al., 2015). 
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Comment: 
There were no side effects reported in the one carotenoids supplementation clinical trial. 
No adverse effects other than carotenodermia, a harmless yellowish skin discoloration, 
have been reported with high dietary intake of carotenoids (Institute of Medicine, 2000). 
However, studies on the effect of carotenoid supplementation on AD onset and 
progression are still lacking. 
 
B VITAMINS 
B vitamins are found in many types of foods. Notably, vitamin B12 is principally found 
in red meat. 
 
(Aisen et al., 2008) 
Homocysteine, a marker of hippocampal neuron loss in AD mouse model (Kruman et al., 
2002), has been shown to decrease in serum of patients under B12 plus folic acid 
supplementation (Malouf, Grimley, & Areosa, 2003). Aisen et al. (2008) studied the 
relationship between B vitamins, homocysteine serum levels, and cognitive function.  
Homocysteine level was significantly reduced in 409 subjects with mild to moderate 
cognitive impairment who were given 5 mg folate, 25mg of Vitamin B6, and 1mg of 
Vitamin B12 for 18 months. However, the cognitive performance on the Alzheimer’s 
Disease Assessment Scale-Cognition test was unchanged.  
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(van der Zwaluw et al., 2014) 
In another trial with 3000 elderly patients with differing cognitive statuses, there was the 
same decrease in homocysteine levels in the treatment group taking vitamin B12 and 
folic acid. However, there was again no significant impact upon the cognitive 
performance of the participants, this time measured with a Mini-Mental State 
Examination after two years of treatment or placebo. 
 
(Rommer et al., 2016) 
In a study of patients with cognitive impairment and normal cognitive function who were 
supplemented with vitamins B1, B6, B12, and folic acid for 3 months, the Mini-Mental 
State Examination score was not significantly higher in the experimental supplemented 
group. Levels of carbonyl proteins, markers of oxidative stress, were significantly higher 
in patients in the control group. Though the treatment group overall did not do any better 
on the Mini-Mental State Examination, there was a significant correlation between lower 
carbonyl protein concentrations and a better performance on the Mini-Mental State 
Examination.  
 
Comment: 
While B vitamins may be correlated with homocysteine levels, no effect of homocysteine 
on cognition has been shown. However, a wider cognitive battery might be used in future 
studies as the Mini-Mental State Examination, applied in the above studies, only has 30 
questions. It may not be very sensitive as it is recommended as a screening tool rather 
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than as a diagnostic indicator of dementia (Tombaugh & McIntyre, 1992). Importantly, 
no adverse effects have been associated with B vitamin supplementation. 
 
PHOSPHATIDYLSERINE 
Phospholipids have been shown to have various effects on the brain’s glucose 
metabolism, neurotransmitter release, anti-oxidation environment, and long-term 
structural changes. Administering phosphatidylserine to rats in a study increased their 
acetylcholine release at synapses while also increasing their performance in a cognitive 
test (Suzuki et al., 2001). In an animal and cell culture study, phosphatidylserine 
supplementation improved glutathione peroxidase activity and reduced nitric mono-oxide 
levels in the liver, both indicating decreased oxidative stress (Chaung et al., 2013). 
Another study of microglial cells showed that administering phosphatidylserine to 
microglia decreased inflammatory mediators and free radical production induced by 
Abeta peptides (Hashioka et al., 2007). Phosphatidylserine was shown to cause structural 
neuronal effect in a study on aging rats where phosphatidylserine supplementation over 2 
years of the rats’ lifetime led to the maintenance of dendritic spines as the treated rats 
aged compared to the control group that lost 10% of their dendrite spine density (Nunzi, 
Milan, Guidolin, & Toffano, 1987).  
 
Subsequently, several clinical trials have tried to explore supplementation with this 
component, found in high concentrations in soybeans and in bovine brain matter. 142 AD 
patients were studied by Amaducci et al. way back in 1988.  The treatment group was 
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given bovine-derived phosphatidylserine (200mg) for 3 months and exhibited significant 
increases in cognitive performance. A study of 51 patients with AD, led by Crook et al. in 
1992 demonstrated the same effect. Another study of 493 patients with moderate to 
severe cognitive decline treated with bovine derived phosphatidylserine or placebo for six 
months also supported this conclusion. The treatment group had improvements in 
behavioral and cognitive measures at the end of the study (Cenacchi, Bertoldin, Farina, 
Fiori, & Crepaldi, 1993). Metabolism was significantly increased (up 16%) in brain areas 
especially involved in AD over the period of 3 weeks with 500mg/day of 
phosphatidylserine administration (Klinkhammer, Szelies, & Heiss, 1990). Notably, 
Crook et al. (1992) also found that patients who had less severe memory problems 
improved more significantly than those who were worse at baseline, implicating an effect 
of intervention time on disease course. These animal-derived phospholipid trials were 
halted with the heightened risk of mad cow disease transmission from ingesting bovine 
brain matter. Clinical trials continued with vegetarian sources of this essential component 
of the body.  
 
(Moré, Freitas, & Rutenberg, 2014) 
This study of adults with varying degrees of cognitive dysfunction gave the treatment 
group 100mg soy-derived phosphatidylserine and 80mg of soy-derived phosphatidic acid, 
a component of phospholipid synthesis, per day. They found that impaired patients with a 
higher baseline score on the Wechsler Memory Scale, a cognitive assessment of several 
memory domains, received a significantly greater benefit from phosphatidylserine and 
	27 
phosphatidic acid supplementation than those who had a lower initial score. The less 
impaired treatment group exhibited a significant increase in their cognitive performance 
after 3 months. Participants with lower initial scores actually showed a decline in 
cognitive performance. (Figure 5). 
 
Interestingly, when both groups were given the option to continue treatment under the 
double-blind condition, 43% of the intervention group decided to continue treatment after 
the conclusion of the study, whereas none of the placebo group decided to do so. This 
may have been related to the significant increase in depressive symptoms seen by 
blinded-clinicians in the placebo group, whereas the treatment group did not experience 
the same decline in mood. (Figure 5).  
 
Notably, without consideration of baseline scores, both treatment and placebo conditions 
scored better on cognition after 3 months, potentially indicating a learned-test taking 
effect. This kind of effect must be considered in any study using tests to measure 
cognitive performance. Again, the implications of intervention appear to be stronger the 
earlier in the disease course they occur. No negative side effects were observed. 
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Figure 5. Changes in memory and mood in older adults under phosphatidylserine or 
placebo treatment. A) Test scores on the Wechsler Memory Scale at baseline and at 3 
months in placebo and in phosphatidylserine treatment condition. B) Difference between 
placebo and treatment conditions in group of baseline Wechsler score <69 and baseline 
Wechsler score >68 C) Clinician-scored list of depressive symptoms at baseline and at 3 
months in placebo and treatment conditions. PS= phosphatidylserine WMS=Wechsler 
Memory Scale LDS= List of Depressive Symptoms. (Moré et al., 2014). 
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(Kato-Kataoka et al., 2010) 
This study of 78 adults with mild cognitive impairment excluded the severely cognitively 
impaired. This group had fairly high scores on cognitive tests, with the exception of 
delayed verbal recall, one of the first domains of memory to experience impairment in the 
AD pathogenesis. Of these adults, there was a significant improvement in the delayed 
verbal recall score in the treatment group after 6 months compared to placebo. This 
improvement was more easily seen for those with relatively lower scores at baseline 
within the group of mildly cognitively impaired adults. This opposes the findings of other 
studies. Perhaps there is a very narrow range of early impairment where intervention is 
best, rather than the idea of the earlier intervention, the better. More trials must be 
conducted, especially as there have not been many normal adult trials as of yet. Also, one 
might hypothesize that the less cognitively impaired of this early stage group may have 
been too mildly impaired for test sensitivity. No side effects were reported. 
 
(Richter, Herzog, Lifshitz, Hayun, & Zchut, 2013) 
This study demonstrated that soy-derived phosphatidylserine improved memory 
recognition, memory recall, executive functions, and mental flexibility with significance 
(Table 6). However, this study also did not have a placebo, hence the very strong 
causative relationships must be approached cautiously. No side effects were reported.  
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Table 6. Effect of phosphatidylserine on cognitive test after 6 weeks and 12 weeks as 
compared to baseline test scores. (Richter, Herzog, Lifshitz, Hayun, & Zchut, 2013). 
 
 
 
(Hartmann et al., 2014) 
Providing a mix of nutrients that rate-limit phospholipid synthesis in patients with mild or 
very mild AD for 24 weeks showed an increase in phosphatidylcholine species that are 
depleted in AD. Again, a reliable observation of this and earlier studies was that efficacy 
was shown only in patients in the early stages of the disease, indicating again that early 
intervention is paramount. 
 
Comment: 
There are some inconsistencies in the areas of cognitive function that improved, with 
some studies demonstrating overall cognition improvement and some with only specific 
domains. It appears that cognition did improve through supplementation of this core 
component of neurons. More studies are needed, especially to investigate patients at 
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different time points of the disease. No significant side effects were observed for any of 
these trials. 
 
MICRONUTRIENT COMBINATIONS  
B vitamins, vitamin C, and polyphenols 
(Morillas-Ruiz et al., 2010) 
The researchers here used a formula of B vitamins, vitamin C, and antioxidant 
polyphenols derived from apple concentrate, lemon concentrate, and green tea extract. 
They had three groups: no impairment, mild impairment, and moderate impairment. They 
gave half of each group the treatment formula and the other half placebo for 8 months. 
The levels of homocysteine were significantly less in the participants who received the 
treatment formula compared to placebo (Figure 6). Homocysteine is a marker of 
oxidative stress, that multiple studies have associated with AD progression (Morris, 
2003), suggesting that these participants received an effect from a multi-nutrient anti-
oxidation mechanism of the formula. Interestingly, the moderate stage received the only 
significant antioxidant effect in the treatment condition, showing a much smaller increase 
in homocysteine over the course of the study compared to the moderate stage patients in 
placebo condition (Figure 6). This study is notable in that they specifically divided adults 
into groups of no, mild, or moderate cognitive impairment so that an effect can be seen 
between stages of the disease. Contrary to other studies, it appears that the protective 
effect of the formula against oxidation was greater later on in the disease’s time course.   
 
	32 
 
Figure 6. Change in homocysteine concentrations in serum of patients with different 
baseline cognitive status over 8 months of placebo or antioxidant supplementation 
treatment. (Morillas-Ruiz et al., 2010). 
 
 
Remington studies 
(Remington, Chan, Paskavitz, & Shea, 2009) 
This small study tested a 9-month nutrient intervention of a combination of folate, 
Vitamin E, vitamin B12, S-adenosyl methionine, N-acetyl cysteine, and acetyl-L-
carnitine in 12 moderate to late stage AD patients. The results indicated a significant 
delay in decline on cognitive tests compared to placebo. These findings, like the 
Morillas-Ruiz et al. (2010) results, are unique because they appear to show significant 
improvement in advanced AD patients. There were no side effects reported. 
 
(Chan, Paskavitz, Remington, Rasmussen, & Shea, 2009) 
In this study of the same formulation as above, 14 early AD patients were treated for 12 
months. Performance in cognition, behavior, and activities of daily living were improved 
or maintained from baseline as compared to placebo. When compared to treatment group 
	33 
or placebo group in studies on donepezil and other experimental pharmacologic 
compounds for AD treatment, these study participants performed as well or better. 
Notably, this study showed efficacy for those in an earlier stage of the disease. Both of 
these studies had small cohorts and should be tested on a larger scale. 
 
(Remington et al., 2015) 
In this Phase II double-blind study continuing Remington et al.’s 2009 work, 106 AD 
patients received the formula for 6 months. At the 3 month marker, the treatment group 
with this combinatorial nutritional intervention already showed improvement on multiple 
cognitive tests compared to placebo. When put on an open-label treatment extension, 
both original placebo and treatment groups showed improvement or maintenance in 
cognitive performance. This study used more participants and replicated the results seen 
earlier.  
 
Comment:  
The studies coming out of this combined compound treatment seem promising in that 
multiple tests and domains of AD seemed to show improvement. However, given that an 
AD therapeutic is something that will need to be used for years, demonstrating clinical 
safety requires a longer evaluation in further research. Again, if halting AD progression 
was the reliable end result of this treatment, perhaps evaluating the effect of this formula 
in AD prevention is warranted. 
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Souvenaid studies 
Souvenaid, or Fortasyn Connect, is a 125-ml breakfast drink that contains the following 
phosphatide precursors and cofactors: docosahexaenoic acid, eicosapentaenoic acid, 
uridine-5'-mono-phosphate, choline, phospholipids, antioxidants, selenium, and B, C, and 
E vitamins. In clinical trials, it is compared with a placebo of equal calories.  
 
Uridine, choline, and docosahexanoic acid, some of the components of this formula, act 
in conjunction to enhance synaptic neurotransmitter release, number of dendritic spines, 
and number of postsynaptic neuron connections in animal models synergistically 
(Cansev, Wurtman, Sakamoto, & Ulus, 2008). Other components of this formula have 
shown varied efficacies as single nutrients in human clinical trials discussed within this 
paper. The rationale behind Souvenaid is the synergistic or holistic properties of its 
components. The formula provides materials for phospholipid and neuronal membrane 
synthesis to combat synaptic loss in AD pathology by providing a beneficial environment 
for synapse formation and function. In an AD mouse model, Souvenaid was shown to 
decrease neurodegeneration, Abeta peptide formation and plaque burden (Broersen et al., 
2007). 
 
(Kamphuis et al., 2011) 
A treatment group received Souvenaid. A significant correlation was only found between 
treatment and cognitive score on the Alzheimer’s Dementia Assessment Scale-cognition 
in patients who had a high baseline score compared to those with a low baseline score. 
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Additionally, those who had the strictest compliance to the Souvenaid treatment received 
a greater cognitive benefit. Notably, a significant correlation between treatment and 
performance in Activities of Daily Living was only found in Souvenaid treated patients 
considered to have a “low” baseline Body Mass Index. One side effect noted was that 
nutrient combination therapy resulted in an increased Body Mass Index in the treatment 
group, although the placebo group was actually given an iso-caloric mixture. Again, in 
this study, the patients in an earlier stage of the disease seem to receive greater benefit 
from dietary intervention.  
 
The relationship between the existing Body Mass Index and nutritional intervention 
needs elucidation. It is possible that the higher percentage of body fat was too detrimental 
to their overall brain health for the treatment to show an effect. Alternatively, the lower 
percentage of body fat combined with nutrient intervention could have potentiated the 
effect. 
 
(Scheltens et al., 2010) 
In a 12 week double-blind trial of 225 AD patients at 29 different treatment centers in 5 
countries, the Souvenaid treatment group showed significant improvement in delayed 
verbal recall, the domain in which impairment appears in the early stages of AD 
pathology. The other cognitive and behavioral tests showed no significance. In patients 
with very mild AD (Mini-Mental State Examination score 24-26) only, the treatment 
group also showed significant improvement in their Wechsler Memory Scale verbal 
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recall scores compared to controls. There were no significant effects between treatment 
and placebo groups for patients with lower baseline Mini-Mental scores. 18.2% of 
patients in the treatment group were identified as good “responders” to the formula. This 
categorization was defined by two out of three of any of the following: by an Alzheimer’s 
Disease Assessment Scale point decrease ≥4 points, by an Activities of Daily Living 
score of ≥4 points increase, and/or by blinded-clinician interview evaluation. The placebo 
group had only 7% fall into this categorization. 
 
There were no side effects observed. The compliance with treatment was 95% in the 225 
participants, showing promise for ease of administration and compliance if recommended 
in clinic. This study is notable because of its multicenter recruitment and hence larger 
sample size. However, not all the effects of the smaller-scale study could be replicated, 
only one specific kind of recall, though the effect was see in another cognitive 
performance score controlling for lower baseline scores. That Wechsler score effect seen 
in patients with mild AD compared to no effect seen in later stages reiterates the 
importance of focusing on prevention early on rather than attempting treatment in later 
stages once neurons have been lost. The combination of multiple different nutrients is 
also a novel and promising approach to a complex and multifactorial disease. Perhaps 
further research should focus on synapse formation to prevent AD pathology rather than 
solely reducing the oxidative stress of the environment.  
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(Scheltens et al., 2012) 
Results from this follow-up study on Souvenaid indicated significant changes in 
functional connectivity of synapses in the brain, detectable by electroencephalography, 
after 24 weeks of treatment. The memory domain of a neuropsychological test battery 
significantly improved. Souvenaid had no reported side effects here, after 24 weeks, 
either. 
 
(Waal et al., 2014)  
This 24-week study of 179 patients with mild AD was also done using 
electroencephalography to elucidate brain structure and network connectivity changes 
related to memory performance in the trial. The local neuron-to neuron connectivity and 
peak frequency of brain activity decreased significantly in the control group, typical of 
progressive AD. The treatment group’s network connectivity was unchanged, suggesting 
a protective effect of Souvenaid on synapses. However, this effect did not manifest itself 
detectably in memory performance. This replicates Scheltens et al.’s (2012) findings on 
connectivity, though does not support the cognitive effect Scheltens et al. (2012) found.  
 
Comment:  
The effect shown in mild AD supports the importance of early intervention. The 
observation of a sole effect in healthy-weight individuals in one domain of AD underlies 
the importance of overall health for a successful intervention. The correlation of 
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electroencephalography-based connectivity measures with cognitive status and treatment 
effects needs further evaluation.  
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DISCUSSION ON MICRONUTRIENTS 
 
Vitamin E, vitamin C, the B vitamins, and the carotenoids, are reported to affect 
oxidative stress in the brain and plasma environment. However, it seems difficult to link 
lowered oxidative stress with increased cognitive function. It is also unclear whether it is 
possible to modulate the oxidative stress through dietary intervention.  
 
Some researchers evaluated the effect of a combination of several nutrients and reported 
benefits in various cognitive domains. 
 
Besides anti-oxidation, the other focus seems to be protection of the synapses or neuronal 
membranes using phosphatidylserine or a combination of precursors and cofactors (see 
Souvenaid studies). The results are mixed and there are still too few studies to support a 
conclusive effect for these treatments.  
 
The overall health benefits of the micronutrients or food sources from which these 
micronutrients are derived have already been documented and supported as part of a 
healthy diet. Further research on the cognitive benefits of these nutrients may be still 
warranted. Recommendations for further research are as follows. The longest 
micronutrient study investigated in this paper was only 2 years long, with the vast 
majority of these studies conducted over only several months. The AD pathogenesis is 
likely decades long while dietary factors affect human lives in their entirety. Thus, these 
studies must be conducted over longer periods of time and in a preclinical stage in order 
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to gauge true effect. What may make this necessary research difficult is that having a 
control group deprived of these micronutrients is unethical because of the proven overall 
health benefits conferred. 
 
Besides an increased length of treatment time and earlier intervention study, further 
large-scale research trials need to examine different dosages and frequencies considering 
complete and consistent AD biomarker status of participants. Further studies must 
modulate these factors to decipher the boundaries of safety, efficacy, and suitability for 
different populations, if a completely reliable and beneficial nutrient intervention is 
found. 
 
SAFETY AND COMPLIANCE FOR DIETARY INTAKE VS. SUPPLEMENTATION 
Since significant side effects were not seen in any of the studies, one may conclude that 
supplement intake as nutritional intervention is a low-risk approach to treating AD. 
Nevertheless, supplements are pharmacologically active compounds and must be closely 
examined over a longer period of treatment time. Over-supplementation and self-
medication with vitamins or other micronutrients is presumed safe and over-the-counter 
availability supports this presumption. The presumption of unconditional safety leads to 
under-reporting by citizens on adverse events while taking them, leading to an even less 
comprehensive knowledge of what risks may exist with high dosages (Woo, 2007). A 
survey by the Food and Drug Administration estimates that it is notified of < 1% of all 
adverse events associated with dietary supplements{(Woo, 2007) (Talati & Gurnani, 
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2009)}. An example of a known danger of Vitamin C over-supplementation, for example, 
is the formation of oxalate crystals and subsequent kidney damage {(McHugh, Graber, & 
Freebairn, 2008) (Lamarche, Nair, Peguero, & Courville, 2011)}. This public health issue 
should be addressed by spreading awareness and educating about the limited benefit 
derived from supplements and that more is not better and can be potentially harmful. 
Further research on safety and dosage must be done. In general, supplements that are 
taken regularly and at high dosages should be taken only with physician consultation 
(Woo, 2007).  
 
In an epidemiological study of almost 3000 individuals (Morris, 2003), the effect of 
Vitamin E taken in the diet was indiscernible from Vitamin E from supplements. 
However, more studies are also needed to examine intake of bioavailable micronutrients 
from their natural source rather than supplementation because both may be delivery 
options in the future of cognitive health prevention. It is understandable why mainly only 
supplements have been tested in randomized clinical trials, because dietary intake is a 
much more difficult study to recruit for and to control for. All of a person’s dietary intake 
over an extended period of time must be controlled, compared to giving them a pill to 
take every day. Practically, supplementation may be easier to implement for some 
vulnerable populations who may not have access to fresh food sources, although in other 
populations, incorporation in the diet may have higher compliance than remembering to 
take a pill every day. Further research in the natural versus supplemental sources must be 
	42 
conducted, considering potentially differential effects and compliance between the two 
delivery methods. 
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MACRONUTRIENTS, OTHER LIFESTYLE FACTORS, and AD 
 
MACRONUTRIENTS AND INSULIN 
Insulin is released by pancreatic-beta cells into the circulation after meals of 
carbohydrates, fats, and proteins. Higher-glycemic index foods with more carbohydrates 
cause a more rapid spike in insulin in plasma, while a high-saturated fat diet causes 
insulin resistance (Koska et al., 2016). A different effect of diet is seen in the CSF. In 
adults with mild cognitive impairment on a low-glycemic, low-saturated fat diet, insulin 
concentration increased in the CSF, whereas in adults with normal cognition on a high-
glycemic high-saturated fat diet, insulin concentration decreased in the CSF (Bayer-
Carter et al., 2011). After crossing the blood-brain barrier, insulin has the ability to 
modulate glucose intake for neuronal function and to interact with the metabolism and 
processing of the amyloid precursor protein and its breakdown product, the Abeta peptide 
(Plum, Schubert, & Brüning, 2005). This is likely just one of the ways the brain can be 
affected by dietary habits (Plum, Schubert, & Brüning, 2005) as hyperinsulinemia was 
shown to result in increased CSF Abeta42 peptide and F2-isoprostane concentrations 
(Fishel et al., 2005).  
 
(Ho et al., 2004) 
This study treated AD mouse model with a high-fat diet that promoted insulin-resistance. 
The treatment increased soluble Abeta peptide generation as well as increasing the 
amyloid plaque burden seen in the brain. A functional decrease was seen in the insulin 
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receptor signal transduction pathway in the brain. The mice also showed impaired 
performance on a cognitive task. The dietary intervention remarkably showed impacts on 
many features of the brain pathology, increasing both the soluble and fibrillar Abeta 
peptides as well as impairing the insulin signaling of the neurons, supporting a causative 
effect of diet on AD-associated pathology in this model. 
 
(Felice et al., 2009) 
In human hippocampal neuron cultures, Felice et al. found that Abeta breakdown 
products downregulated insulin receptors on the neuronal membranes prior to eventual 
Abeta-induced permanent damage. With administration of insulin to the cultures, the 
pathological Abeta binding effect was prevented. Interestingly, if insulin was 
administered to cultures while the insulin receptor was inhibited, Abeta binding actually 
increased. Therefore, insulin has a physiological downstream signaling pathway through 
its receptor to prevent Abeta binding, rather than binding to ectopic sites on the Abeta 
peptides themselves. CSF insulin’s protective downstream effects may be investigated as 
prevention or therapy against the deterioration of synapses and the impaired cognitive 
function caused by Abeta peptides.  
 
(Bayer-Carter et al., 2011)  
In this study, adults with mild cognitive impairment and normal adults were randomly 
assigned to two treatment groups for 4 weeks: a low-saturated fat low-glycemic diet or a 
high-saturated fat high-glycemic diet.  
	45 
 
The high-glycemic diet significantly decreased CSF insulin in the normal adult group. 
The high-glycemic diet condition caused increased F2-isoprostane in healthy adults, 
while those with cognitive impairment at baseline maintained their concentration of the 
F2-isoprostane marker of oxidative stress. The high-glycemic diet condition for both 
normal and impaired groups increased the concentration of dysfunctional lipid-depleted 
apolipoproteins. Normally, apolipoproteins are chaperone proteins that facilitate 
clearance of Abeta peptides, slowing down the AD pathogenesis. Lipid-depleted 
apolipoproteins show a 10-fold decreased ability to clear Abeta peptides (Tokuda et al., 
2000) and in this study, were significantly associated with the increased number of 
soluble Abeta peptides seen in under high-glycemic treatment condition. The high-
glycemic diet treatment caused no change in cognitive performance for either normal or 
impaired groups. 
 
The high-glycemic high-saturated fat diet exacerbated features of AD pathology 
including dysfunctional apolipoproteins and soluble Abeta peptides. Insulin in this 
treatment only decreased in the normal adult CSF. The implications of this are unclear, 
although it could be postulated that the impaired neurons had suboptimal energy uptake 
to begin with, so blood glucose spikes were permitted and not responded to with an 
insulin decrease in the brain. Oxidative stress was only shown to increase in healthy 
adults but not impaired adults. It is not clear if diet can modulate oxidative stress once the 
AD pathology presents symptomatically, as discussed earlier with micronutrient 
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modulators of oxidation. Cognitive performance was maintained, though when compared 
to the low-glycemic treatment condition’s improved cognitive performance, perhaps there 
was a detrimental effect (especially if learned-test-taking effect is considered). 
 
The low-glycemic low-saturated fat diet condition increased insulin in the CSF of the 
mild cognitive impairment group. The low-glycemic low-saturated fat diet showed 
reduced F2-isoprostane concentrations in both normal and cognitively impaired older 
adults. An increase in concentration of normal apolipoproteins with treatment was 
observed. The low-glycemic non-insulin-promoting diet decreased Abeta peptide levels 
in the CSF of normal adults, counteracting the expected buildup of Abeta in CSF over 
time in normal adults (Figure 2). Interestingly, the treatment increased levels of CSF 
Abeta peptide in the mild cognitive impairment group. However, this could be attributed 
to increased CSF insulin’s signaling protection against parenchymal Abeta binding. The 
resultant decreased Abeta retention in the brain could lead to more Abeta floating freely 
in CSF. This also actually reverses the observed pathologically decreased CSF Abeta 
seen in symptomatic adults (Figure 2). Thus, the low-glycemic diet caused both normal 
and mild cognitively impaired groups to experience a positive change in their distribution 
of Abeta. The low-glycemic diet treatment improved cognitive performance.  
The effects of the low-glycemic diet in normal and impaired adults appear beneficial by 
diminishing Abeta distribution and oxidative stress and improving cognitive 
performance. The low-glycemic diet caused a significant increase in insulin within the 
CSF of the mild cognitive impairment group, but not the normal adults. One may 
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speculate that an impaired brain has less optimal energy uptake to begin with, so the low-
glycemic diet elicited a more emergent need and response for glucose uptake in the 
impaired patients compared to normal patients. Diet-induced insulin changes in the CSF 
should be researched further. Both treatment groups’ diets should be compared to 
baseline diets in future studies and continued for a longer period of time if possible. 
Figure 7 below demonstrates theoretical entry points into the Alzheimer’s pathway 
through which genetic, dietary or insulinic factors modulate pathogenesis. 
 
 
 
Figure 7. Model of endogenous and exogenous factors affecting neuronal 
degradation and metabolism of Abeta in the CNS. Aβ= amyloid beta peptide. ApoE= 
apolipoprotein E. BBB= blood-brain barrier. CNS= central nervous system. E2+ = 
apolipoprotein E2 genotype. E4+ = apolipoprotein E4 genotype.   High diet= high-
glycemic, high-saturated fat diet. Low diet= low-glycemic, low-saturated fat diet. 
(Hanson et al., 2013).	
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(Hanson et al., 2013) 
In another diet intervention study, a randomized clinical trial of 47 normal or mild 
cognitively impaired seniors, was conducted. Members of both groups were randomly 
assigned to a high-glycemic high-saturated fat diet treatment or a low-glycemic low-
saturated fat diet treatment for 4 weeks.  
 
Lower-glycemic diet significantly decreased soluble (lipid-depleted) Abeta42 
concentration, whereas the higher-glycemic diet maintained their Abeta42 concentration. 
There was no significant effect of low-glycemic or high-glycemic diet on soluble 
Abeta40 levels (Figure 8). 
 
 
Figure 8. Low diet and High diet effect on Abeta concentrations in the CSF. A) LD 
Abeta42 levels and B) LD Abeta40 levels. (Hanson et al., 2013). 
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Under low-glycemic diet treatment, normal and impaired groups’ levels of CSF insulin 
negatively correlated with levels of soluble Abeta40 and Abeta42 in CSF (Figure 9). The 
high-glycemic diet treatment condition did not show significant association between CSF 
insulin levels and soluble Abeta42 or Abeta40 levels.  
 
 
 
Figure 9. Correlations between CSF insulin levels and CSF Abeta concentrations 
under Low diet treatment. A) Abeta42 concentration and B) Abeta40 concentration. 
(Hanson et al., 2013). 
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The low-glycemic diet appeared to decrease soluble Abeta42 in the brain, possibly 
through potentiating insulin’s protective effect in the brain. The high-glycemic diet did 
not cause any significant increases in Abeta or show association between insulin levels 
and Abeta. Perhaps further studies should examine the diets that patients were consuming 
before the study, to see the effect of a change in diet relative to baseline diet on brain 
physiology. 
 
Comment: 
These diet intervention studies were associated with more normal levels of CSF insulin, 
Abeta peptides, apolipoproteins, cognitive performance, and oxidative stress. Controlling 
patients’ diets in these trials shows the multivariate influence of nutrition on brain 
physiology, giving support to further research investigating the intricate interaction 
between a patient’s lifestyle and neurodegenerative disease later in life.  
 
These trials point to hyperinsulinemic diet’s negative effects and a low-glycemic low-
saturated fat diet’s positive effects counteracting AD pathology, possibly through an 
insulin signaling mechanism. Insulin and diet clearly exert an influence on brain 
physiology, possibly affecting the development of neurodegeneration and thus merit 
further investigation. 
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OTHER LIFESTYLE FACTORS AND THEIR SYNERGY WITH DIET 
AD is a complex, multifactorial disease. As a feature of its long incubation and time-
course, many factors in each individual’s lifestyle have a chance to influence it. Studies 
below have demonstrated synergy or potentiation between factors such as exercise, diet, 
mental and social activities in affecting the progression of AD. 
 
EXERCISE 
(Larson et al., 2006) 
This 4-8 year-long association study of people older than 65 years old found a strong 
association between frequency of exercise and dementia presentation. The rate of 
dementia was 13 out of 1000 people who exercised 3 or more times a week compared to 
19.7 out of 1000 people for the group who exercised less than 3 times a week. The group 
that exercised regularly essentially reduced their risk of AD by 32%.  
 
Another notable finding was the results of patients who had poor physical mobility at 
baseline. Exercising regularly gave these patients an even greater risk reduction than the 
overall group of regular exercisers. Perhaps the exercise led to a proportionally greater 
improvement in brain perfusion to support neuronal function than in the already 
physically mobile regular exercisers. Regardless, the importance of exercise is 
demonstrated for all adults. Notably, because the study started before any of the 
participants developed dementia, a case could be made for lifestyle changes before 
clinical presentation influencing pathology.  
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(Berchtold, Castello, & Cotman, 2010)  
Mice that were frequently exercised showed improvement in their maze-seeking behavior 
compared to sedentary animals. Additionally, the level of brain-derived neurotrophic 
factor in exercised mice was significantly greater than the level of neurotrophic factor in 
sedentary mice. The best-performing mice were in fact those who had a 1-week delay 
after exercise before they began cognitive training, demonstrating that exercise’s benefit 
to the brain is not just immediate but perpetrates over time.  
 
(Wu et al., 2008)  
This study showed that docosahexaenoic acid improves cognitive function and 
neuroplasticity and increases protection against neuronal damage in rats.  A 12-day 
treatment with docosa-hexaenoic acid-rich diet increased levels of brain-derived 
neurotrophic factor, a factor in memory formation and storage. In the frequent-exercise 
group within the treatment condition, the levels of neurotrophic factor increased even 
more. Docosahexaenoic acid appears to have a potentiating or synergistic effect with 
exercise on cognition and synaptic plasticity, even within just 12 days.  
 
(Kesse-Guyot et al., 2011)  
In an association study of 2135 middle-aged adults, participants were scored on their 
overall adherence to guidelines for macronutrient intake, caloric intake, and physical 
activity outlined by the French National Nutrition and Health Program (Estaquio et al., 
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2009). The adherence score was strongly associated with memory domains assessed in 
cognitive testing 13 years later, particularly verbal memory, one of the most prominently-
impaired domains in AD. When any single factor of the National Program’s guidelines 
was removed or controlled for, the association still remained significant. An important 
takeaway from this result is that dietary factors and exercise appear to be inextricably 
connected, working together to affect the brain.  
 
(Baker et al., 2012) 
High-intensity physical activity, but not low-intensity exercise such as walking, could 
offset the studied effects of high-carbohydrate high-saturated fat diet on increasing CSF 
Abeta in normal adults. Additionally, in adults with mild cognitive impairment, high 
intensity physical activity can increase the beneficial effects of the low-glycemic low-
saturated fat diet.  
 
Comment:  
Exercise appears to influence AD presentation, potentially through the increase of blood 
flow to the brain. Adding a dietary factor such as docosahexanoic acid or guidelines for 
overall diet such as in the French National Program study or in a low-glycemic low-
saturated fat diet seem to exert a positive effect synergistically with exercise. Another 
consideration in studying the benefit of exercise should be physical activity’s effect on 
improving insulin sensitivity. The interaction between physical activity/diet and insulin 
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sensitivity appears important in light of the above discussion on the effect of 
hyperinsulinemia on Abeta production. 
 
MENTAL ACTIVITIES   
(Perani et al., 2017) 
Cognitive reserve confers protection against the clinical effects of neuronal degeneration. 
The degree of fluency and frequency of usage of multiple languages may be a lifestyle 
factor that increases cognitive reserve as bilingualism and the frequeny of usage of the 
two languages correlated significantly with an increased age of dementia onset.  
 
(Verghese et al., 2003) 
In a study following 469 subjects older than 75 years of age for 5 years, frequency of 
participation in leisure activities including reading, playing board games, musical 
instruments, and dancing were associated with reduced dementia risk.  
 
Comment: 
Activities such as those listed likely stimulate neural networks, boosting cognitive reserve 
and thus delaying AD presentation. Controlled trials are needed to confirm the direct 
protective effect of mental activities such as speaking two languages, reading, dancing, 
etc. 
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MULTIFACTORIAL LIFESTYLE INTERVENTION 
(Ngandu et al., 2015) 
This study of 1200 participants between 60-77 years old with cognitive performance 
lower than expected for age used a multifactorial intervention over 2 years. At baseline, 
both the control group and the experimental group were given advice about a healthy 
diet, physical, cognitive, and social activities. In the following months, the treatment 
group received personal and group nutrition counseling 12 times. The nutritionists 
advised individuals’ diets with the following recommendations: A balance of protein, fat, 
and carbohydrate calories, adequate dietary fiber, minimal salt and alcohol, high fruit and 
vegetable consumption, wholegrain cereal products, low fat milk and meat products, 
sugar intake of less than 50 g/day, substituting vegetable oils for animal fats, and fish 
consumption twice a week. The treatment group also received individually tailored 
strength and aerobic training at the gym with physiotherapists. Cognitive training 
consisted of computerized and group activities. Social activities consisted of the 
numerous group meetings required for intervention treatment condition. 
 
In the treatment group, the overall cognition, executive functioning and processing speed 
significantly improved anywhere from 25% to 150% more than the control group (Figure 
10). Overall memory itself did not show significant advantage from the treatment, 
although post analyses showed significant improvement on more complex memory tests 
in the neuropsychological test battery. 
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Figure 10. The effect of a multidomain lifestyle intervention on cognitive functions 
over 24 months. Blue= control group. Red = intervention group. Upper left quadrant) 
neuropsychological test battery (NTB) total score. Upper right quadrant) executive 
functioning score. Lower left quadrant) processing speed score Lower right quadrant) 
memory score. (Ngandu et al., 2015). 
 
Comment: 
The strength of this study is the very comprehensive intervention, the long period of time 
and the many participants recruited. These intervention factors should be examined 
individually to determine if the effect was mainly due to one particular domain or if the 
cooperative effect of the intervention domains was greater than the sum of their parts. 
Additionally, the positive lifestyle factors of the control group were not accounted for in 
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the analyses. The degree of adherence to the intervention in the treatment group was also 
not accounted for. If these two factors were considered, perhaps the results would have 
been even more significant.  
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DISCUSSION ON MACRONUTRIENTS AND OTHER LIFESTYLE FACTORS 
 
Diet as a whole, particularly carbohydrate and saturated fat intake that promote 
hyperinsulinemia, appears to have an effect on the physiology of the brain, even on a 
relatively short-term basis of diet intervention. Macronutrients affect changes in the 
concentration of apolipoproteins and soluble Abeta peptides, compounds that have been 
implicated for their role in neurodegeneration.  
 
Diet can also modulate the function or expression of CSF insulin, a compound that has 
shown interaction with soluble Abeta in vitro and in animal studies and whose post-
prandial effect should be investigated further in clinical trials. A forthcoming challenge is 
the ethical impossibility of studying the effect of a hyperinsulinemic diet vs. a healthy 
diet for a longer period of time to model effects over a lifetime more accurately. This is 
because a high-carbohydrate, high-saturated fat diet is already implicated in negative 
health outcomes. Hence, many individuals are already considering a low-carbohydrate, 
low-saturated fat diet for its other well-supported benefits. No significant side effects of 
low-glycemic low-saturated fat diets and increasing frequency or intensity of exercise are 
reported. In order for clinicians to focus on making the most impactful and effective 
recommendations by targeting at-risk and particularly responsive populations, continued 
research on this diet for cognitive benefit must accompany research on predictive 
biomarkers and risk factors. 
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There are many enduring environmental factors that have the potential to affect an 
individual’s health over the course of his or her life. The degree to which these factors 
affect the development of AD should continue to be studied, as many studies so far show 
promising results. It is not as simple as the intake of one micronutrient, but rather a 
combination of dietary nutrients and other lifestyle choices such as mental stimulation, 
social activities, and exercise that seem to act holistically upon cognitive function and 
maintaining cognitive reserve. As these factors are present throughout one’s life, further 
research is required on how these variables work together early on to prevent cognitive 
decline many years later. A prime example is the 2011 Kesse-Guyot et al.’s 13 year-long 
study started when its cohort was middle-aged and cognitively normal. The results 
showing a significant difference in memory correlated with adherence to a set of dietary 
guidelines and exercise in those 13 years. When any factor of the diet or exercise was 
controlled for, the significance still remained. 
 
In conclusion, as interventional effects of lifestyle on AD progression begin far before 
clinical presentation, they represent a potent and hopeful focus for successful AD 
prevention that presently appears to be the best option to combat the impending AD 
epidemic.   
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